South Asian Journal of Engineering and Technology Research Article

Open Access Full Text Article 152(2025) 79-89 DOI: 10.26524/sajet.2025.15.9

Emerging Mechanisms of Antibiotic Resistance in Multidrug-Resistant Pathogens

Pavan. T.K, Manju. K, Ravikumara, Syed Baker, Niranjan Raj. S*

Department of Studies in Microbiology, Karnataka State Open University, Mysore.

Corresponding author.
Correspondence: Niranjan Raj. S
E-mail: niruraj@gmail.com

Article info
Received 30th November 2024
Revised form 29th January 2025
Accepted 21st February 2025

Keywords
AMR, Antibiotics, One Health

https://sajet.in/index.php/journal/article/view/314

Abstract
The rapid emergence and dissemination of multidrug-resistant (MDR) pathogens have become a critical challenge to global health, threatening the effectiveness of current antimicrobial therapies. While classical mechanisms of resistance—such as enzymatic degradation, efflux pumps, and target modification—remain significant, recent studies have identified a range of emerging and novel resistance strategies. These include plasmid-mediated resistance genes like mcr-1, CRISPR-Cas regulatory systems, small regulatory RNAs, and phage-mediated gene transfers, many of which contribute to the dynamic evolution of resistance. Environmental and clinical factors, including antibiotic misuse in healthcare and agriculture, inadequate sanitation, and global mobility, further exacerbate the spread of resistant strains. Advanced diagnostic tools, particularly genomic and bioinformatic platforms, have enhanced our ability to detect resistance traits, but equitable access to these technologies remains limited. To combat this escalating crisis, innovative therapeutic approaches such as phage therapy, antimicrobial peptides, and gene-targeted treatments are being explored. A unified One Health strategy that integrates surveillance, stewardship, and cross-sector collaboration is essential. This paper reviews the current landscape of resistance mechanisms in MDR pathogens, highlights key environmental and clinical drivers, and discusses strategic interventions necessary to preserve antibiotic efficacy and safeguard future public health.

1. INTRODUCTION

Antibiotic resistance represents one of the most pressing global health concerns of the 21st century. Widespread and often inappropriate use of antibiotics in clinical, veterinary, and agricultural settings has accelerated the emergence of resistant pathogens (Salam et al., 2023). Multidrug-resistant (MDR) organisms—those resistant to three or more classes of antibiotics—pose a severe threat to public health due to limited treatment options and increased mortality rates. MDR infections are not confined to healthcare facilities but have also been detected in communities and environmental

reservoirs (Duin and Paterson 2016). The evolution of resistance mechanisms in bacteria is dynamic and multifaceted, involving both classical strategies and newly emerging genetic and biochemical pathways. Recent technological advances in molecular biology and genomics have helped unravel these novel mechanisms, providing insights into how pathogens adapt and survive even under aggressive antimicrobial pressure (Davies and Davies 2010). This paper aims to provide a comprehensive overview of emerging antibiotic resistance mechanisms in MDR pathogens, discussing both traditional and novel adaptations (Devi et al., 2024). It will also explore the environmental and clinical drivers that facilitate the emergence of these traits, methods of detection, and strategies to combat the growing crisis. By understanding these mechanisms in depth, we can better inform future therapeutic development and public health policies (Samreen et al., 2021).

2. OVERVIEW OF MULTIDRUG-RESISTANT PATHOGENS

Multidrug-resistant (MDR) pathogens are microorganisms that have developed resistance to multiple antibiotics, typically from different structural or functional classes. These organisms are particularly problematic in healthcare settings where vulnerable patients are at increased risk of infection (Macesic et al., 2025). Common MDR bacteria include Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and methicillin-resistant Staphylococcus aureus (MRSA) (Gandra et al., 2018). The World Health Organization and Centers for Disease Control and Prevention have categorized some of these pathogens as “critical” or “urgent” threats due to their ability to evade even last-resort antibiotics such as carbapenems and colistin. These pathogens often harbor multiple resistance genes, either chromosomally encoded or acquired via horizontal gene transfer (Huang et al., 2023). Resistance can be intrinsic or acquired and is often facilitated by plasmids, integrons, and transposons. MDR infections are associated with increased hospital stays, treatment failures, and higher healthcare costs (Li and Webster 2017). As conventional antibiotics lose efficacy, these pathogens continue to spread, especially in immunocompromised populations, intensive care units, and low-resource healthcare settings (Muteeb et al., 2023). Understanding the epidemiology and clinical relevance of these pathogens is essential for developing effective control measures and therapeutic strategies. Surveillance and preventive measures are critical to managing the spread of MDR organisms globally (Duin and Paterson 2016).

3. CLASSICAL MECHANISMS OF ANTIBIOTIC RESISTANCE

Traditional antibiotic resistance mechanisms in bacteria can be grouped into several well-characterized categories. One of the most common is enzymatic degradation, where bacteria produce enzymes like beta-lactamases that inactivate antibiotics by hydrolyzing their functional groups (Pang

et al., 2019). Another major mechanism involves efflux pumps, which actively expel antibiotics from the bacterial cell before they can exert their effects. These pumps can confer resistance to multiple drug classes simultaneously (Gaurav et al., 2023). Target modification is another strategy, whereby bacteria alter the antibiotic's binding site, rendering the drug ineffective. This is seen in resistance to fluoroquinolones and macrolides. Reduced membrane permeability involves changes in porin proteins that limit antibiotic entry into the cell, commonly observed in Gram-negative bacteria (Saxena et al., 2021). Additionally, biofilm formation significantly enhances resistance by creating a physical and chemical barrier that impedes antibiotic penetration and protects bacteria within the biofilm from host immune responses (Mirghani et al., 2022). While these classical mechanisms are well understood, they continue to pose major clinical challenges, especially when combined within the same pathogen. These strategies are not mutually exclusive and can be synergistically employed, resulting in high-level resistance. Understanding these mechanisms provides a foundation for interpreting more complex and emerging resistance pathways discussed in later sections (Qin et al., 2022).

4. EMERGING AND NOVEL MECHANISMS OF RESISTANCE

While classical mechanisms of resistance are well documented, emerging mechanisms provide bacteria with innovative strategies to evade antimicrobial activity (Syed et al., 2019). One such mechanism involves plasmid-mediated resistance, such as the mcr-1 gene, which confers resistance to colistin—a last-resort antibiotic (Gogry et al., 2021). The rapid global spread of such plasmids highlights their potential for epidemic dissemination. Another novel strategy is the use of CRISPR-Cas systems, traditionally associated with bacterial immunity but now being linked to the regulation of resistance genes, potentially through gene silencing or facilitation of horizontal gene transfer (Watters et al., 2021). Small regulatory RNAs (sRNAs) are also emerging as key players, modulating gene expression involved in antibiotic susceptibility. Horizontal gene transfer within biofilms is gaining attention, as close proximity of cells and increased genetic exchange in these environments allow resistance traits to spread rapidly (Burmeister 2015). Some bacteria are also demonstrating phage-mediated resistance evolution, where bacteriophages facilitate the acquisition or transfer of resistance genes. These emerging mechanisms are often more elusive and require advanced molecular tools for detection and understanding (Rostøl and Marraffini 2019). Their discovery underscores the evolutionary ingenuity of bacteria and the urgent need for innovative surveillance and treatment approaches that can keep pace with these developments (Singh 2024).

5. ENVIRONMENTAL AND CLINICAL DRIVERS OF RESISTANCE

The rise of antimicrobial resistance is heavily influenced by environmental and clinical practices. In healthcare settings, overprescription of antibiotics, poor infection control, and the use of broad-spectrum antimicrobials fuel resistance development (Samreen et al., 2021). Antibiotic misuse in livestock and agriculture—including sub-therapeutic dosing for growth promotion—contributes significantly to the environmental load of antibiotic residues and resistant microbes (Van et al., 2020). Wastewater treatment plants, pharmaceutical industry effluents, and hospital waste are major reservoirs of resistance genes, promoting their spread through water, soil, and air. Global travel and trade facilitate the cross-border transmission of MDR pathogens and resistance genes (Mutuku et al., 2022). In many regions, limited access to diagnostic tools and over-the-counter antibiotic availability exacerbates inappropriate use. Moreover, urbanization and poor sanitation infrastructure can lead to environmental contamination and increased human exposure (Polianciuc et al., 2020). Biofilms in natural and artificial settings further enhance the survival of resistant bacteria. Collectively, these drivers form a complex network that sustains the resistance crisis. Addressing them requires a One Health approach, which recognizes the interconnectedness of human, animal, and environmental health. Public health strategies must emphasize antibiotic stewardship, education, regulation, and investment in alternatives to traditional antimicrobials (Cella et al., 2023).

6. DETECTION AND MONITORING OF EMERGING RESISTANCE

Accurate detection and monitoring of emerging resistance mechanisms are crucial for early intervention and containment. Whole-genome sequencing (WGS) and metagenomics have revolutionized surveillance by enabling comprehensive identification of known and novel resistance genes across diverse microbial communities (Sukhum et al., 2019). These tools allow researchers to detect low-abundance resistance traits that may not be evident through traditional culture-based methods. Rapid diagnostic tools, such as PCR-based assays, microarrays, and biosensors, offer timely results that can inform treatment decisions at the point of care (Yamin et al., 2023). Innovations like CRISPR-based diagnostics and nanopore sequencing are being explored for their potential in real-time resistance detection. Additionally, bioinformatics platforms and artificial intelligence are being used to predict resistance patterns and monitor trends over time (Satam et al., 2023). Surveillance programs like the WHO's GLASS (Global Antimicrobial Resistance Surveillance System) provide valuable data for guiding policy and clinical practices globally. However, significant challenges remain, including the cost of genomic tools, limited infrastructure in low-resource settings, and data sharing barriers (Musa et al., 2023). A coordinated, multidisciplinary effort is required to strengthen resistance monitoring and translate findings into actionable strategies. Enhanced detection not only

helps manage individual cases but also mitigates large-scale outbreaks of resistant infections (Mohammed et al., 2025).

7. STRATEGIES TO COMBAT EMERGING RESISTANCE

To counter emerging resistance mechanisms, a multipronged approach is required. Developing novel antibiotics that target unexplored bacterial pathways is critical but time-consuming and costly (Syed et al., 2018). As a complementary strategy, antibiotic adjuvants are being explored to inhibit resistance mechanisms, such as beta-lactamase inhibitors co-administered with beta-lactams (Narendrakumar et al., 2023). Antimicrobial peptides (AMPs) and metal-based nanoparticles (e.g., silver, zinc oxide) offer promising non-traditional therapies that bypass conventional resistance mechanisms. Phage therapy, using bacteriophages to specifically target and lyse bacteria, has gained renewed interest, especially against biofilm-forming and MDR strains (Mdarhri et al., 2022). Additionally, CRISPR-Cas systems can be engineered to selectively target and silence resistance genes, offering gene-level control of resistance. Beyond therapeutics, vaccination, improved diagnostics, and infection control measures are essential for reducing the need for antibiotics in the first place (Kundar and Gokarn 2022). Global efforts to enforce antibiotic stewardship, regulate agricultural use, and invest in research are gaining momentum. International collaboration is essential, with the One Health framework offering a sustainable model. While challenges such as resistance to new drugs and regulatory barriers exist, ongoing innovation and global coordination offer hope in reversing the tide of resistance (Ribeiro et al., 2019).

8. CASE STUDIES

Several recent outbreaks have underscored the real-world impact of emerging resistance. In 2015, the discovery of the mcr-1 gene in E. coli from a pig in China marked the first reported plasmid-mediated colistin resistance, sparking global concern due to its potential for horizontal gene transfer (Devi et al., 2024). Subsequent studies found mcr-1 in human, animal, and environmental samples across continents. Another notable case involves New Delhi metallo-beta-lactamase-1 (NDM-1), first identified in 2008 in India and linked to resistance against nearly all beta-lactams. The gene rapidly spread across Europe, Asia, and North America through travel and medical tourism (Pang et al., 2019). In the U.S., Carbapenem-resistant Enterobacteriaceae (CRE) have been implicated in several hospital outbreaks, resulting in increased mortality and healthcare costs. Recently, a strain of Acinetobacter baumannii resistant to all commercially available antibiotics was isolated from a war-injured patient, highlighting the implications of resistance in conflict zones (Saxena et al., 2021). These

cases exemplify the urgent need for international surveillance, rapid diagnostics, and containment strategies. Each incident also reinforces how environmental, clinical, and societal factors converge to facilitate resistance emergence. Analyzing such case studies helps in understanding pathogen evolution, resistance dissemination, and policy shortcomings (Samreen et al., 2021).

9. CHALLENGES AND FUTURE PERSPECTIVES

Despite technological and scientific progress, significant challenges persist in the fight against antibiotic resistance (Baker et al., 2020). One of the foremost obstacles is the slow development pipeline for new antibiotics, hindered by high costs, regulatory hurdles, and low commercial incentives (Rostøl and Marraffini 2019). Additionally, resistance to novel therapeutics can develop rapidly, diminishing long-term efficacy. Surveillance efforts remain uneven globally, especially in low-income regions with inadequate infrastructure for diagnostics or genomic analysis (Satam et al., 2023; Baker & Perianova, 2019). Public awareness and education are also lacking in many communities, contributing to misuse and overuse of antibiotics. Furthermore, coordination between sectors—human health, veterinary medicine, agriculture, and the environment—is still limited despite the promotion of the One Health approach. Looking forward, future perspectives emphasize precision medicine, AI-driven diagnostics, and global policy alignment as key solutions (Ribeiro et al., 2019). Collaborative research across disciplines, incentivizing innovation, and enhancing access to healthcare will be central to these efforts. Environmental interventions to reduce antibiotic pollutants and resistance reservoirs will also play a role. Ultimately, overcoming these challenges requires political will, sustained investment, and global solidarity to curb this escalating threat (Singh 2024).

10. CONCLUSION

The rise of multidrug-resistant pathogens and their evolving mechanisms of antibiotic resistance represent a critical threat to public health and global healthcare systems. While classical resistance strategies continue to challenge clinical management, the emergence of novel mechanisms—such as plasmid-mediated resistance, CRISPR-associated regulation, and biofilm-enhanced gene transfer—underscore the remarkable adaptability of pathogenic bacteria. These mechanisms are driven by a combination of clinical misuse, environmental contamination, and global interconnectedness. Advanced genomic tools and bioinformatics are enhancing our ability to detect and monitor resistance patterns, but these must be coupled with innovative therapeutic approaches, regulatory reforms, and public health interventions to be effective. From phage therapy to nanoparticle-based antimicrobials, new treatment paradigms offer hope but face hurdles in translation and accessibility. The future of resistance management lies in a unified One Health strategy that integrates human,

animal, and environmental health. Immediate action is required at both national and international levels to limit the spread of resistance, preserve the efficacy of existing antibiotics, and invest in sustainable solutions. Failure to act decisively could usher in a post-antibiotic era where common infections become untreatable.

Acknowledgement

Nill

Funding

No funding was received to carry out this study.

REFERENCES

1. ALAOUI MDARHRI, H., BENMESSAOUD, R., YACOUBI, H., SEFFAR, L., GUENNOUNI ASSIMI, H., HAMAM, M., BOUSSETTINE, R., FILALI-ANSARI, N., LAHLOU, F. A., DIAWARA, I., ENNAJI, M. M., & KETTANI-HALABI, M. (2022). ALTERNATIVES THERAPEUTIC APPROACHES TO CONVENTIONAL ANTIBIOTICS: ADVANTAGES, LIMITATIONS AND POTENTIAL APPLICATION IN MEDICINE. ANTIBIOTICS, 11(12), 1826. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS11121826
2. BAKER, S., & PERIANOVA, O. V. (2019). BIO-NANOBACTERICIDES: AN EMANATING CLASS OF NANOPARTICLES TOWARDS COMBATING MULTI-DRUG RESISTANT PATHOGENS. SN APPLIED SCIENCES, 1(7), 699.
3. BAKER, S., PERIANOVA, O. V., PRUDNIKOVA, S. V., KUZMIN, A., POTKINA, N. K., KHOHLOVA, O. Y., & LOBOVA, T. I. (2020). PHYTOGENIC NANOPARTICLES TO COMBAT MULTI DRUG RESISTANT PATHOGENS AND PHOTOCATALYTIC DEGRADATION OF DYES. BIONANOSCIENCE, 10(2), 486-492.
4. BURMEISTER, A. R. (2015). HORIZONTAL GENE TRANSFER: FIGURE 1. EVOLUTION, MEDICINE, AND PUBLIC HEALTH, 2015(1), 193–194. HTTPS://DOI.ORG/10.1093/EMPH/EOV018
5. CELLA, E., GIOVANETTI, M., BENEDETTI, F., SCARPA, F., JOHNSTON, C., BORSETTI, A., CECCARELLI, G., AZARIAN, T., ZELLA, D., & CICCOZZI, M. (2023). JOINING FORCES AGAINST ANTIBIOTIC RESISTANCE: THE ONE HEALTH SOLUTION. PATHOGENS, 12(9), 1074. HTTPS://DOI.ORG/10.3390/PATHOGENS12091074
6. DAVIES, J., & DAVIES, D. (2010). ORIGINS AND EVOLUTION OF ANTIBIOTIC RESISTANCE. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 74(3), 417–433. HTTPS://DOI.ORG/10.1128/MMBR.00016-10
7. DEVI, N. S., MYTHILI, R., CHERIAN, T., DINESHKUMAR, R., SIVARAMAN, G. K.,

JAYAKUMAR, R., PRATHABAN, M., DURAIMURUGAN, M., CHANDRASEKAR, V., & PEIJNENBURG, W. J. G. M. (2024). OVERVIEW OF ANTIMICROBIAL RESISTANCE AND MECHANISMS: THE RELATIVE STATUS OF THE PAST AND CURRENT. THE MICROBE, 3, 100083. HTTPS://DOI.ORG/10.1016/J.MICROB.2024.100083

8. DOS S. RIBEIRO, C., VAN DE BURGWAL, L. H. M., & REGEER, B. J. (2019). OVERCOMING CHALLENGES FOR DESIGNING AND IMPLEMENTING THE ONE HEALTH APPROACH: A SYSTEMATIC REVIEW OF THE LITERATURE. ONE HEALTH, 7, 100085. HTTPS://DOI.ORG/10.1016/J.ONEHLT.2019.100085
9. GANDRA, S., TSENG, K. K., ARORA, A., BHOWMIK, B., ROBINSON, M. L., PANIGRAHI, B., LAXMINARAYAN, R., & KLEIN, E. Y. (2018). THE MORTALITY BURDEN OF MULTIDRUG-RESISTANT PATHOGENS IN INDIA: A RETROSPECTIVE, OBSERVATIONAL STUDY. CLINICAL INFECTIOUS DISEASES, 69(4), 563–570. HTTPS://DOI.ORG/10.1093/CID/CIY955
10. GAURAV, A., BAKHT, P., SAINI, M., PANDEY, S., & PATHANIA, R. (2023). ROLE OF BACTERIAL EFFLUX PUMPS IN ANTIBIOTIC RESISTANCE, VIRULENCE, AND STRATEGIES TO DISCOVER NOVEL EFFLUX PUMP INHIBITORS. MICROBIOLOGY, 169(5). HTTPS://DOI.ORG/10.1099/MIC.0.001333
11. GOGRY, F. A., SIDDIQUI, M. T., SULTAN, I., & HAQ, Q. MOHD. (2021). CURRENT UPDATE ON INTRINSIC AND ACQUIRED COLISTIN RESISTANCE MECHANISMS IN BACTERIA. FRONTIERS IN MEDICINE, 8. HTTPS://DOI.ORG/10.3389/FMED.2021.677720
12. HUANG, E., YANG, X., LEIGHTON, E., & LI, X. (2023). CARBAPENEM RESISTANCE IN THE FOOD SUPPLY CHAIN. JOURNAL OF FOOD PROTECTION, 86(7), 100108. HTTPS://DOI.ORG/10.1016/J.JFP.2023.100108
13. KUNDAR, R., & GOKARN, K. (2022). CRISPR-CAS SYSTEM: A TOOL TO ELIMINATE DRUG-RESISTANT GRAM-NEGATIVE BACTERIA. PHARMACEUTICALS, 15(12), 1498. HTTPS://DOI.ORG/10.3390/PH15121498
14. LI, B., & WEBSTER, T. J. (2017). BACTERIA ANTIBIOTIC RESISTANCE: NEW CHALLENGES AND OPPORTUNITIES FOR IMPLANT-ASSOCIATED ORTHOPEDIC INFECTIONS. JOURNAL OF ORTHOPAEDIC RESEARCH, 36(1), 22–32. HTTPS://DOI.ORG/10.1002/JOR.23656
15. MACESIC, N., UHLEMANN, A.-C., & PELEG, A. Y. (2025). MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS. THE LANCET, 405(10474), 257–272. HTTPS://DOI.ORG/10.1016/S0140-6736(24)02081-6
16. MIRGHANI, R., SABA, T., KHALIQ, H., MITCHELL, J., DO, L., CHAMBI, L., DIAZ, K.,

KENNEDY, T., ALKASSAB, K., HUYNH, T., ELMI, M., MARTINEZ, J., SAWAN, S., & RIJAL, G. (2022). BIOFILMS: FORMATION, DRUG RESISTANCE AND ALTERNATIVES TO CONVENTIONAL APPROACHES. AIMS MICROBIOLOGY, 8(3), 239–277. HTTPS://DOI.ORG/10.3934/MICROBIOL.2022019

17. MOHAMMED, A. M., MOHAMMED, M., OLEIWI, J. K., OSMAN, A. F., ADAM, T., BETAR, B. O., GOPINATH, S. C. B., & IHMEDEE, F. H. (2025). ENHANCING ANTIMICROBIAL RESISTANCE STRATEGIES: LEVERAGING ARTIFICIAL INTELLIGENCE FOR IMPROVED OUTCOMES. SOUTH AFRICAN JOURNAL OF CHEMICAL ENGINEERING, 51, 272–286. HTTPS://DOI.ORG/10.1016/J.SAJCE.2024.12.005
18. MUSA, K., OKOLIEGBE, I., ABDALAZIZ, T., ABOUSHADY, A. T., STELLING, J., & GOULD, I. M. (2023). LABORATORY SURVEILLANCE, QUALITY MANAGEMENT, AND ITS ROLE IN ADDRESSING ANTIMICROBIAL RESISTANCE IN AFRICA: A NARRATIVE REVIEW. ANTIBIOTICS, 12(8), 1313. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS12081313
19. MUTEEB, G., REHMAN, M. T., SHAHWAN, M., & AATIF, M. (2023). ORIGIN OF ANTIBIOTICS AND ANTIBIOTIC RESISTANCE, AND THEIR IMPACTS ON DRUG DEVELOPMENT: A NARRATIVE REVIEW. PHARMACEUTICALS, 16(11), 1615. HTTPS://DOI.ORG/10.3390/PH16111615
20. MUTUKU, C., GAZDAG, Z., & MELEGH, S. (2022). OCCURRENCE OF ANTIBIOTICS AND BACTERIAL RESISTANCE GENES IN WASTEWATER: RESISTANCE MECHANISMS AND ANTIMICROBIAL RESISTANCE CONTROL APPROACHES. WORLD JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 38(9). HTTPS://DOI.ORG/10.1007/S11274-022-03334-0
21. NARENDRAKUMAR, L., CHAKRABORTY, M., KUMARI, S., PAUL, D., & DAS, B. (2023). B-LACTAM POTENTIATORS TO RE-SENSITIZE RESISTANT PATHOGENS: DISCOVERY, DEVELOPMENT, CLINICAL USE AND THE WAY FORWARD. FRONTIERS IN MICROBIOLOGY, 13. HTTPS://DOI.ORG/10.3389/FMICB.2022.1092556
22. PANG, Z., RAUDONIS, R., GLICK, B. R., LIN, T.-J., & CHENG, Z. (2019). ANTIBIOTIC RESISTANCE IN PSEUDOMONAS AERUGINOSA: MECHANISMS AND ALTERNATIVE THERAPEUTIC STRATEGIES. BIOTECHNOLOGY ADVANCES, 37(1), 177–192. HTTPS://DOI.ORG/10.1016/J.BIOTECHADV.2018.11.013
23. POLIANCIUC, S. I., GURZĂU, A. E., KISS, B., ȘTEFAN, M. G., & LOGHIN, F. (2020). ANTIBIOTICS IN THE ENVIRONMENT: CAUSES AND CONSEQUENCES. MEDICINE AND PHARMACY REPORTS. HTTPS://DOI.ORG/10.15386/MPR-1742
24. QIN, S., XIAO, W., ZHOU, C., PU, Q., DENG, X., LAN, L., LIANG, H., SONG, X., & WU, M.

(2022). PSEUDOMONAS AERUGINOSA: PATHOGENESIS, VIRULENCE FACTORS, ANTIBIOTIC RESISTANCE, INTERACTION WITH HOST, TECHNOLOGY ADVANCES AND EMERGING THERAPEUTICS. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 7(1). HTTPS://DOI.ORG/10.1038/S41392-022-01056-1

25. ROSTØL, J. T., & MARRAFFINI, L. (2019). (PH)IGHTING PHAGES: HOW BACTERIA RESIST THEIR PARASITES. CELL HOST & MICROBE, 25(2), 184–194. HTTPS://DOI.ORG/10.1016/J.CHOM.2019.01.009
26. SALAM, MD. A., AL-AMIN, MD. Y., SALAM, M. T., PAWAR, J. S., AKHTER, N., RABAAN, A. A., & ALQUMBER, M. A. (2023). ANTIMICROBIAL RESISTANCE: A GROWING SERIOUS THREAT FOR GLOBAL PUBLIC HEALTH. HEALTHCARE, 11(13), 1946. HTTPS://DOI.ORG/10.3390/HEALTHCARE11131946
27. SAMREEN, AHMAD, I., MALAK, H. A., & ABULREESH, H. H. (2021A). ENVIRONMENTAL ANTIMICROBIAL RESISTANCE AND ITS DRIVERS: A POTENTIAL THREAT TO PUBLIC HEALTH. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 27, 101–111. HTTPS://DOI.ORG/10.1016/J.JGAR.2021.08.001
28. SAMREEN, AHMAD, I., MALAK, H. A., & ABULREESH, H. H. (2021B). ENVIRONMENTAL ANTIMICROBIAL RESISTANCE AND ITS DRIVERS: A POTENTIAL THREAT TO PUBLIC HEALTH. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 27, 101–111. HTTPS://DOI.ORG/10.1016/J.JGAR.2021.08.001
29. SATAM, H., JOSHI, K., MANGROLIA, U., WAGHOO, S., ZAIDI, G., RAWOOL, S., THAKARE, R. P., BANDAY, S., MISHRA, A. K., DAS, G., & MALONIA, S. K. (2023). NEXT-GENERATION SEQUENCING TECHNOLOGY: CURRENT TRENDS AND ADVANCEMENTS. BIOLOGY, 12(7), 997. HTTPS://DOI.ORG/10.3390/BIOLOGY12070997
30. SAXENA, S., SPAINK, H. P., & FORN-CUNÍ, G. (2021). DRUG RESISTANCE IN NONTUBERCULOUS MYCOBACTERIA: MECHANISMS AND MODELS. BIOLOGY, 10(2), 96. HTTPS://DOI.ORG/10.3390/BIOLOGY10020096
31. SINGH, A. (2024). ARTIFICIAL INTELLIGENCE FOR DRUG REPURPOSING AGAINST INFECTIOUS DISEASES. ARTIFICIAL INTELLIGENCE CHEMISTRY, 2(2), 100071. HTTPS://DOI.ORG/10.1016/J.AICHEM.2024.100071
32. SUKHUM, K. V., DIORIO-TOTH, L., & DANTAS, G. (2019). GENOMIC AND METAGENOMIC APPROACHES FOR PREDICTIVE SURVEILLANCE OF EMERGING PATHOGENS AND ANTIBIOTIC RESISTANCE. CLINICAL PHARMACOLOGY & THERAPEUTICS, 106(3), 512–524. HTTPS://DOI.ORG/10.1002/CPT.1535
33. SYED, B., PRASAD, M. N., KUMAR, K. M., & SATISH, S. (2018). BIOCONJUGATED NANO-

BACTERICIDAL COMPLEX FOR POTENT ACTIVITY AGAINST HUMAN AND PHYTOPATHOGENS WITH CONCERN OF GLOBAL DRUG RESISTANT CRISIS. SCIENCE OF THE TOTAL ENVIRONMENT, 637, 274-281.

34. SYED, B., PRUDNIKOVA, S. V., PERIANOVA, O. V., ZHARKOV, S. M., KUZMIN, A., CHOUHAN, R. S., ... & SINGH, M. (2019). PHYTOGENIC SYNTHESIS OF AG BIONANO-ANTIBIOTICS AGAINST ESKAPE DRUG RESISTANT COMMUNITIES IN KRASNOYARSK, SIBERIA. JOURNAL OF CLUSTER SCIENCE, 30, 589-597.
35. VAN DUIN, D., & PATERSON, D. L. (2016A). MULTIDRUG-RESISTANT BACTERIA IN THE COMMUNITY. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 30(2), 377–390. HTTPS://DOI.ORG/10.1016/J.IDC.2016.02.004
36. VAN DUIN, D., & PATERSON, D. L. (2016B). MULTIDRUG-RESISTANT BACTERIA IN THE COMMUNITY. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 30(2), 377–390. HTTPS://DOI.ORG/10.1016/J.IDC.2016.02.004
37. VAN, T. T., YIDANA, Z., SMOOKER, P. M., & COLOE, P. J. (2020). ANTIBIOTIC USE IN FOOD ANIMALS WORLDWIDE, WITH A FOCUS ON AFRICA: PLUSES AND MINUSES. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 20, 170–177. HTTPS://DOI.ORG/10.1016/J.JGAR.2019.07.031
38. WATTERS, K. E., KIRKPATRICK, J., PALMER, M. J., & KOBLENTZ, G. D. (2021). THE CRISPR REVOLUTION AND ITS POTENTIAL IMPACT ON GLOBAL HEALTH SECURITY. PATHOGENS AND GLOBAL HEALTH, 115(2), 80–92. HTTPS://DOI.ORG/10.1080/20477724.2021.1880202
39. YAMIN, D., USKOKOVIĆ, V., WAKIL, A., GONI, M., SHAMSUDDIN, S., MUSTAFA, F., ALFOUZAN, W., ALISSA, M., ALSHENGETI, A., ALMAGHRABI, R., FARES, M., GAROUT, M., AL KAABI, N., ALSHEHRI, A., ALI, H., RABAAN, A., ALDUBISI, F., YEAN, C., & YUSOF, N. (2023). CURRENT AND FUTURE TECHNOLOGIES FOR THE DETECTION OF ANTIBIOTIC-RESISTANT BACTERIA. DIAGNOSTICS, 13(20), 3246. HTTPS://DOI.ORG/10.3390/DIAGNOSTICS13203246.